Press Releases
Cocrystal Announces Board Changes
Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
Cocrystal Pharma Reports 2018 Third Quarter Financial Results and Provides Corporate Update
Cocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
